Voya Investment Management LLC Sells 2,890 Shares of TransMedics Group, Inc. $TMDX

Key Points

• Voya Investment Management LLC has reduced its holdings in TransMedics Group by 24.7%, selling 2,890 shares and holding 8,818 shares worth approximately $593,000.
• A number of institutional investors, including Smartleaf Asset Management LLC and Quarry LP, have increased their stakes in TransMedics Group during the first quarter.
• TransMedics Group recently reported earnings of $0.92 per share, significantly exceeding analysts' expectations, with quarterly revenue up 37.7% year-over-year at $157.37 million.

Voya Investment Management LLC lessened its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 24.7% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,818 shares of the company's stock after selling 2,890 shares during the period. Voya Investment Management LLC's holdings in TransMedics Group were worth $593,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of TMDX. NBC Securities Inc. purchased a new position in TransMedics Group during the 1st quarter valued at about $25,000. Smartleaf Asset Management LLC increased its stake in shares of TransMedics Group by 44.3% during the first quarter. Smartleaf Asset Management LLC now owns 440 shares of the company's stock valued at $30,000 after purchasing an additional 135 shares in the last quarter. Quarry LP lifted its holdings in shares of TransMedics Group by 88.5% during the first quarter. Quarry LP now owns 592 shares of the company's stock valued at $40,000 after purchasing an additional 278 shares during the last quarter. Hager Investment Management Services LLC lifted its holdings in shares of TransMedics Group by 38.3% during the first quarter. Hager Investment Management Services LLC now owns 740 shares of the company's stock valued at $50,000 after purchasing an additional 205 shares during the last quarter. Finally, CWM LLC boosted its position in shares of TransMedics Group by 20.1% in the 1st quarter. CWM LLC now owns 925 shares of the company's stock worth $62,000 after purchasing an additional 155 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

TMDX has been the subject of a number of analyst reports. Stifel Nicolaus began coverage on TransMedics Group in a research report on Thursday, September 4th. They set a "hold" rating and a $115.00 price objective for the company. Evercore ISI began coverage on TransMedics Group in a research note on Tuesday, September 16th. They issued an "outperform" rating and a $155.00 target price on the stock. Piper Sandler restated an "overweight" rating and set a $145.00 price target (up from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a research report on Monday, August 25th. Finally, Wall Street Zen cut shares of TransMedics Group from a "buy" rating to a "hold" rating in a research note on Saturday, August 30th. Six equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $125.40.

TransMedics Group Stock Down 3.0%

TransMedics Group stock opened at $113.90 on Friday. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $160.80. The stock has a fifty day simple moving average of $116.18 and a two-hundred day simple moving average of $108.39. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61. The firm has a market cap of $3.88 billion, a price-to-earnings ratio of 59.02 and a beta of 2.18.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.44. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The firm had revenue of $157.37 million for the quarter, compared to the consensus estimate of $146.64 million. During the same period in the prior year, the company posted $0.35 earnings per share. The company's quarterly revenue was up 37.7% on a year-over-year basis. TransMedics Group has set its FY 2025 guidance at EPS. Equities analysts predict that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.